Interim analysis of COVID-19 vaccine effectiveness against
Severe Acute Respiratory Infection due to laboratory-confirmed
SARS-CoV-2 among individuals aged 50 years and older, ECDC
multi-country study – first update

x 2022

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update

BACCI, Sabrina a Nathalie NICOLAY

Základní údaje

Originální název

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update

Autoři

BACCI, Sabrina a Nathalie NICOLAY

Vydání

2022

Nakladatel

FNUSA, ECDC

Další údaje

Jazyk

angličtina

Typ výsledku

Projekty výzkumu a vývoje

Obor

30230 Other clinical medicine subjects

Stát vydavatele

Švédsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

COVID-19

Kód RIV

RIV/00216224:14110/22:00127691

Organizační jednotka

Lékařská fakulta

Klíčová slova česky

Technical Report; COVID-19; SARI

Klíčová slova anglicky

Technical Report; COVID-19; SARI

Štítky

FNUSA, user

Příznaky

Mezinárodní význam

Změněno: 5. 4. 2023 13:32, Mgr. Tereza Miškechová

Anotace

V originále

Evaluating the real-world performance of COVID-19 vaccines is critical to understanding the risks and benefits of COVID-19 vaccination programmes. ECDC has been building infrastructure to allow regular monitoring of COVID-19 vaccine effectiveness over time, using a multi-country approach that involves studies implemented in different settings across EU/EEA countries. The project allows for progressive inclusion of more countries over time and the same generic protocol is used across all countries. This update reports on a multi-country study that aims to estimate vaccine effectiveness against severe COVID-19 disease, by assessing it in individuals hospitalised for SARI. This ECDC hospital vaccine effectiveness study began at the end of 2020 and, as of 25 October 2021, has recruited 10 participating countries across the EU/EEA (Belgium, Croatia, Czechia, France, Greece, Ireland, Luxembourg, Malta, Portugal and Spain), including 42 hospitals among them (ranging from 1 to 13 hospitals per country). Five countries began their vaccination campaigns at the end of December 2020 and five in early January 2021. The analysis presented in this report aims to estimate vaccine effectiveness among SARI patients aged 50 years and older, from the first vaccination campaign start date on 27 December 2020 up to and including 30 June 2021. This end date was selected to provide a study period before wide circulation of the Delta variant of concern (VOC) in the European region.

Návaznosti

90128, velká výzkumná infrastruktura

Název: CZECRIN III

Citovat

BACCI, Sabrina a Nathalie NICOLAY. Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update. FNUSA, ECDC, 2022.

@misc{2243543,
   author = {Bacci, Sabrina and Nicolay, Nathalie},
   keywords = {Technical Report; COVID-19; SARI},
   language = {eng},
   publisher = {FNUSA, ECDC},
   title = {Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update},
   url = {https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-of-COVID-19-vaccine-effectiveness-against-SARI-2022.pdf},
   year = {2022}
}

TY  - JFULL
ID  - 2243543
AU  - Bacci, Sabrina - Nicolay, Nathalie
PY  - 2022
TI  - Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update
PB  - FNUSA, ECDC
KW  - Technical Report
KW  - COVID-19
KW  - SARI
UR  - https://www.ecdc.europa.eu/sites/default/files/documents/Interim-analysis-of-COVID-19-vaccine-effectiveness-against-SARI-2022.pdf
N2  - Evaluating the real-world performance of COVID-19 vaccines is critical to understanding the risks and benefits of COVID-19 vaccination programmes. ECDC has been building infrastructure to allow regular monitoring of COVID-19 vaccine effectiveness over time, using a multi-country approach that involves studies implemented in different settings across EU/EEA countries. The project allows for progressive inclusion of more countries over time and the same generic protocol is used across all countries. This update reports on a multi-country study that aims to estimate vaccine effectiveness against severe COVID-19 disease, by assessing it in individuals hospitalised for SARI. This ECDC hospital vaccine effectiveness study began at the end of 2020 and, as of 25 October 2021, has recruited 10 participating countries across the EU/EEA (Belgium, Croatia, Czechia, France, Greece, Ireland, Luxembourg, Malta, Portugal and Spain), including 42 hospitals among them (ranging from 1 to 13 hospitals per country). Five countries began their vaccination campaigns at the end of December 2020 and five in early January 2021. The analysis presented in this report aims to estimate vaccine effectiveness among SARI patients aged 50 years and older, from the first vaccination campaign start date on 27 December 2020 up to and including 30 June 2021. This end date was selected to provide a study period before wide circulation of the Delta variant of concern (VOC) in the European region.
ER  -

BACCI, Sabrina a Nathalie NICOLAY. \textit{Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update}. FNUSA, ECDC, 2022.

Podrobný výpis o publikaci